Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
This was 6 months ago
Locationonline
ProgrammesNCP Flanders organises this webinar on the Safe and Sustainable by Design Framework: a guidance to scientists developing new chemicals or materials with the aim to make these safer and more sustainable.
It aims to
The Commission Recommendation from 8 December 2022 which announced the Framework reaches beyond HE projects, encouraging also national programmes to take up or industry to apply the framework when developing new chemicals or materials.
A representative of DG Research & Innovation from the European Commission will speak about the purpose of the framework, how it is to be used as part of a projects technical activities and the current status of the testing phase.
In a second part an expert from the Flemish Institute for Technological Research (VITO) will shed some light on the content of the SSbD framework.
There will be time for Q&A at the end of the presentations.
For registration (mandatory) click here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security AI, data & cloud Cybersecurity Defence Space
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.